Compare MLTX & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLTX | ATLC |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.7M | 816.9M |
| IPO Year | N/A | 1999 |
| Metric | MLTX | ATLC |
|---|---|---|
| Price | $14.59 | $62.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $36.33 | ★ $82.83 |
| AVG Volume (30 Days) | ★ 2.0M | 82.2K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.57 |
| EPS | N/A | ★ 5.63 |
| Revenue | N/A | ★ $498,496,000.00 |
| Revenue This Year | N/A | $403.57 |
| Revenue Next Year | N/A | $60.82 |
| P/E Ratio | ★ N/A | $10.91 |
| Revenue Growth | N/A | ★ 33.26 |
| 52 Week Low | $5.95 | $41.37 |
| 52 Week High | $62.75 | $78.91 |
| Indicator | MLTX | ATLC |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 62.68 |
| Support Level | $12.48 | $58.08 |
| Resistance Level | $15.56 | $60.19 |
| Average True Range (ATR) | 0.78 | 2.25 |
| MACD | 0.46 | 0.72 |
| Stochastic Oscillator | 69.76 | 95.70 |
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.